N8 Medical

N8 Medical is a private, clinical-stage company developing antimicrobial coatings for medical devices to combat HAIs and antimicrobial resistance (AMR). Its lead CeraShield-coated endotracheal tube has received FDA Breakthrough Device designation and is cleared for use in several ex-US markets, with FDA approval anticipated. The company leverages significant non-dilutive funding through NIH SBIR grants and is structured under a holding company, N8 Biosciences, with a therapeutic drug development subsidiary, Kinnear Pharmaceuticals.

Ceragenins (CSAs) – synthetic, non-peptide compounds that mimic natural antimicrobial peptides (AMPs), engineered for broad-spectrum, non-leaching, biofilm-preventing coatings (CeraShield) for medical devices.

N8 Medical competes in the antimicrobial medical device coating space against companies using technologies like silver ions, antibiotics (e.g., minocycline/rifampin), and other antimicrobial peptides. Its key differentiation is the Ceragenin platform's stability and broad-spectrum, membrane-targeting mechanism designed to minimize resistance. Established medtech giants with coated device portfolios also represent significant competition.